HomeZEAL • CPH
Zealand Pharma A/S
kr 699.00
Jan 13, 5:20:00 PM GMT+1 · DKK · CPH · Disclaimer
StockDK listed security
Previous close
kr 735.00
Day range
kr 696.00 - kr 730.00
Year range
kr 426.60 - kr 972.00
Market cap
52.20B DKK
Avg Volume
207.94K
P/E ratio
-
Dividend yield
-
Primary exchange
CPH
Financials
Income Statement
Revenue
Net income
(DKK)Sep 2024Y/Y change
Revenue
4.42M-98.51%
Operating expense
360.45M47.08%
Net income
-266.40M-459.29%
Net profit margin
-6.03K-24,148.94%
Earnings per share
-3.77-406.50%
EBITDA
-343.22M-793.69%
Effective tax rate
0.51%
Total assets
Total liabilities
(DKK)Sep 2024Y/Y change
Cash and short-term investments
8.48B436.03%
Total assets
9.63B342.65%
Total liabilities
746.69M108.16%
Total equity
8.88B
Shares outstanding
70.65M
Price to book
5.85
Return on assets
-8.83%
Return on capital
-9.17%
Net change in cash
(DKK)Sep 2024Y/Y change
Net income
-266.40M-459.29%
Cash from operations
-295.33M-162.05%
Cash from investing
-6.07B-3,892.89%
Cash from financing
-272.24M-6,851.93%
Net change in cash
-6.64B-11,806.98%
Free cash flow
-238.27M-53.42%
About
Zealand Pharma A/S is a Danish biotechnology research company, which designs and develops peptide-based medicines, mainly focusing on metabolic diseases like diabetes and obesity. The company's head office is situated in Søborg near Copenhagen, and it has close to 200 employees. In 2018, they opened a subsidiary in the US. Zealand Pharma forms part of the Danish-Swedish life science cluster Medicon Valley. Wikipedia
Founded
Apr 1, 1997
Employees
298
Search
Clear search
Close search
Google apps
Main menu